Flu Shot At-Home Delivery Service Launches

AstraZeneca has launched an innovative at-home delivery service for FLUMIST®, an intranasal influenza vaccine.

According to a press release on August 15, 2025, after verifying eligibility and insurance, FLUMIST will be prescribed and shipped directly to the consumer's home on their chosen date.

The package will include clear administration instructions, storage guidance, and disposal information.

FLUMIST is the first and only seasonal influenza vaccine approved for self-administration by adults aged 18 to 49. A parent or caregiver can also administer it to individuals aged 2 to 17.

Initially approved by the Food and Drug Administration in 2003, eligible individuals and their families can now conveniently protect themselves during the 2025-26 flu season from the comfort of their homes.

Joris Silon, US Country President and Senior Vice President at AstraZeneca, stated in a press release, "The launch of FluMist Home marks a transformational moment in the evolution of influenza protection, providing a simple and accessible option directly to consumers."

He added, "FluMist Home reflects the growing importance of direct-to-consumer offerings and underscores our commitment to continuous innovation, making it easier for people to get vaccinated and stay protected."

Individuals aged 18 and older can visit www.FluMist.com to learn more and place an order. They will be directed to complete a medical screening questionnaire, which a licensed healthcare provider will review to determine eligibility.